Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling

International Journal of Gynecological Pathology

Volumn 27, Issue 2, 2008, Pages 265-273

  Branca, Margherita ^a   Ciotti, Marco ^b   Giorgi, Colomba ^a   Santini, Donatella ^c   Di Bonito, Luigi ^d   Costa, Silvano ^c   Benedetto, Arrigo ^b   Bonifacio, Donatella ^d   Di Bonito, Paola ^a   Paba, Pierluigi ^b   Accardi, Luisa ^a   Syrjänen, Stina ^e   Favalli, Cartesio ^b   Syrjänen, Kari ^a,f  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cervical cancer; CIN; E Cadherin; ERK 1; Laminin receptor; MMP 2; NF B; nm23; Oncogenic human papillomavirus; p16INK4a; PCNA; Progression; Screening; Survival; Survivin; Telomerase; TIMP 2; Topoisomerase 2 ; VEGF C

Indexed keywords

67 KD LAMININ RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLINE; DNA TOPOISOMERASE; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEOSIDE DIPHOSPHATE KINASE NM23; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOPOISOMERASE 2ALPHA; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN C;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; HUMANS; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, LAMININ; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 41349087575     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318159cbc0     Document Type: Article

References (48)

1. Ho CM, Chien TY, Huang SH, et al. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol 2004;93:458-64.
2. Sardi JE, Boixadera MA, Sardi JJ. A critical overview of concurrent chemoradiotherapy in cervical cancer. Curr Oncol Rep 2004;6:463-70.
3. Heilmann V, Kreienberg R. Molecular biology of cervical cancer and its precursors. Curr Womens Health Rep 2002;2:27-33.
4. Yim EK, Park JS. Role of proteomics in translational research in cervical cancer. Expert Rev Proteomics 2006;3:21-36.
5. Syrjänen K, Syrjänen S. Papillomavirus Infections in Human Pathology Chichester, UK: J. Wiley and Sons, 2000.
6. Campo S, ed. Papillomavirus Research: From Natural History to Vaccines and Beyond. Norwich, UK: Caister Academic Press, 2006:1-424.
7. Cheng Q, Lau WM, Chew SH, et al. Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix. Br J Cancer 2002;86:274-81.
8. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
9. Gray LJ, Herington CS. Molecular markers for the prediction of progression of CIN lesions. Int J Gynecol Pathol 2004;23:95-6.
10. Syrjänen KJ. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:118-24.
11. Ferlay L, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC cancer base no 5, version 2.0. Lyon, France: IARC Press, 2004.
12. von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006;103:18-20.
13. Wiley DJ, Monk BJ, Masongsong E, et al. Cervical cancer screening. Curr Oncol Rep 2004;6:497-506.
14. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 2005;(Suppl 1):17-23.
15. Branca M, Costa S, Mariani L, et al. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 2004;25:689-98.
16. INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-65.
17. Branca M, Ciotti M, Santini D, et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004;122:902-11.
18. Branca M, Giorgi C, Santini D, et al. Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006;59:40-7.
19. Branca M, Giorgi C, Santini D, et al. Aberrant expression of a novel inhibitor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-21.
20. Branca M, Giorgi C, Ciotti M, et al. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J Clin Pathol 2006;59:1044-51.
21. Branca M, Giorgi C, Ciotti M, et al. Over-expression of topoisomerase IIa is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol 2006;25:383-92.
22. Branca M, Giorgi C, Ciotti M, et al. Relationship of up-regulation of 67-kD laminin receptor to grade of cervical intraepithelial neoplasia and high-risk HPV types and prognosis in cervical cancer. Acta Cytologica 2006;50:6-15.
23. Branca M, Giorgi C, Ciotti M, et al. Upregulation of nuclear factor-kB (NF-kB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. Diagn Cytopathol 2006;34:555-63.
24. Branca M, Giorgi C, Ciotti M, et al. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus (HPV), virus persistence or disease outcome in cervical cancer. Diagn Cytopathol 2006;34:739-48.
25. Branca M, Giorgi C, Ciotti M, et al. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res 2006;26:1543-56.
26. Branca M, Giorgi C, Ciotti M, et al. Upregulation of proliferating cell nuclear antigen (PCNA) is closely associate with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Obstet Gynecol Reprod Biol 2007;130:223-31.
27. Branca M, Giorgi C, Ciotti M, et al. Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. Eur J Gynaecol Oncol 2006;27:215-23.
28. Costa S, Terzano P, Santini D, et al. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2001;80:67-73.
29. Costa S, Terzano P, Santini D, et al. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 2001;116:729-37.
30. Costa S, Simone PD, Venturoli S, et al. Factors predicting human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 2003;90:358-65.
31. Seed PT, Tobias A. Summary statistics for diagnostic tests. Stata Tech Bull 2001;59:9-12.
32. Santopietro R, Shabalova I, Petrovichev N, et al. Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, cyclin A in predicting cervical intraepithelial neoplasia, high-risk human papillomavirus infections and their outcome in women screened in three new independent states of the former Soviet Union. Cancer Epidemiol Biomarkers Prev 2006;15:1250-6.
33. Jamora C, Fuchs E. Intercellular adhesion, signaling and cytoskeleton. Nat Cell Biol 2002;4:101-8.
34. Wilding J, Vousden KH, Soutter WP, et al. E-Cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res 1996;56:5285-92.
35. Al Moustafa AE, Foulkes WD, Benlimame N, et al. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 2004;23:350-8.
36. Crusius K, Rodriguez I, Alonso A. The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. Virus Genes 2000;20:65-9.
37. Kabsch K, Alonso A. The human papillomavirus type 16 (HPV-16) E5 protein sensitizes human keratinocytes to apoptosis induced by osmotic stress. Oncogene 2002;21:947-53.
38. Ruutu M, Peitsaro P, Johansson B, et al. Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integration. Int J Cancer 2002;100:318-26.
39. Huang SM, McCance DJ. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 2002;76:8710-21.
40. Finzer P, Kuntzen C, Soto U, et al. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 2001;20:4768-76.
41. Bhat UG, Raychaudhuri P, Beck WT. Functional interaction between human topoisomerase IIalpha and retinoblastoma protein. Proc Natl Acad Sci U S A 1999;96:7859-64.
42. Satterwhite DJ, White RL, Matsunami N, et al. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein. Cancer Res 2000;60:6989-94.
43. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
44. Peitsaro P, Ruutu M, Syrjänen S, et al. Divergent expression changes of telomerase and E6/E7 mRNA, following integration of human papillomavirus type 33 in cultured epithelial cells. Scand J Infect Dis 2004;36:302-4.
45. Endoh T, Tsuji N, Asanuma K, et al. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 2005;305:300-11.
46. Mei ZZ, Zheng XF, Dong -, et al. Inhibiting expression of human telomerase reverse transcriptase promotes degradation of survivin protein. Ai Zheng 2005;24:525-30.
47. Utrera-Barillas D, Salcedo-Vargas M, Gariglio-Vidal P, et al. H-ras and Nm23-H1 gene expression and proteolytic activity in squamous cell carcinoma of the uterine cervix. Arch Med Res 2000;31:172-81.
48. Syrjänen K, Naud P, Derchain SM, et al. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study. Anticancer Res 2005;25:3469-80.